Genomtec Stock

Genomtec EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Genomtec (GMT.WA) as of Jul 24, 2026 is -6.78. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -8.59 — a change of -21.07% (higher).

EV/EBIT

-6.78

YoY

-21.07%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Genomtec is 2026 -6.78 . EV/EBIT (Enterprise Value to EBIT) of Genomtec was 2025 -8.59 . It decreases by -21.07% higher compared to the previous year.

The Genomtec EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-13.52 base
Jan 1, 2022
-9.47 base
Jan 1, 2023
-15.24 base
Jan 1, 2024
-9.47 base
YEARPRICE-TO-EBIT
2024 -9.47
2023 -15.24
2022 -9.47
2021 -13.52
2020 -
2019 -
Access this data via the Eulerpool API
Get Free API Key

Genomtec Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Genomtec's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Genomtec's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Genomtec's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Genomtec grows earnings faster than its peers.

Genomtec Stock analysis

What does Genomtec do? Genomtec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomtec stock

EV/EBIT (Enterprise Value to EBIT) of Genomtec is -6.78 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Genomtec

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Genomtec